Emerging therapies for the treatment of hepatitis C

  • Opportunities to treat infection with hepatitis C virus (HCV) are evolving rapidly. From the introduction of interferon-α monotherapy in 1992 to the approval of telaprevir- and boceprevir-based triple therapies with pegylated interferon-α and ribavirin in 2011, the chances of curing patients infected with HCV genotype 1 have improved from <10% to approximately 70%. Significant further improvements are on the horizon, which may well cure virtually all hepatitis C patients with an all-oral, interferon-free regimen in the very near future. These exciting developments are reviewed in the present article.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Christian LangeGND, Ira M. Jacobson, Charles M. Rice, Stefan ZeuzemORCiDGND
URN:urn:nbn:de:hebis:30:3-347134
DOI:https://doi.org/10.1002/emmm.201303131
ISSN:1715-4684
ISSN:1757-4676
Parent Title (English):EMBO molecular medicine
Publisher:Wiley-VCH
Place of publication:Weinheim
Document Type:Article
Language:English
Year of Completion:2013
Date of first Publication:2013/09/16
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2014/07/25
Tag:NS3-4A protease inhibitor; NS5B polymerase inhibitor; directly acting antiviral agents; hepatitis C virus; interferon-free
Volume:6
Issue:1
Page Number:12
First Page:4
Last Page:15
Note:
© 2013 The Authors. This is an open access article under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0/ , which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
HeBIS-PPN:366010662
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 3.0